• Ikaria Inc., of Hampton, N.J., gained approval in Australia for Lucassin (terlipressin) in the treatment of hepatorenal syndrome (HRS) Type 1, a type of kidney failure, in patients with advanced liver cirrhosis who are being considered for a kidney transplant.